info@seagull-health.com
SeagullHealth
search
Wainua(Eplontersen)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Wainua(Eplontersen) Instructions:Uses,Dosage, Side Effects
WAINUA (eplontersen) is a transthyretin-directed antisense oligonucleotide approved for treating polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). By degrading TTR mRNA, it reduces the production of abnormal TTR protein, slowing disease progression.
Administered monthly via subcutaneous injection, WAINUA requires vitamin A supplementation due to its effect on serum vitamin A levels. Clinical trials demonstrated significant improvements in neuropathy and quality of life compared to placebo. Its safety profile includes manageable adverse effects such as decreased vitamin A and vomiting.
WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
The recommended dosage is 45 mg administered by subcutaneous injection once monthly. Remove the autoinjector from refrigeration 30 minutes prior to injection to allow warming to room temperature. Administer into the abdomen, upper thigh region, or back of the upper arm (if administered by a healthcare provider or caregiver). For missed doses, administer as soon as possible and resume monthly dosing from the most recent administration date.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
